"If there's a word you're going to be hearing more of in the next four years, it's going to be 'transparency.'"

— Daniel Schultz, MD, director of FDA's Center for Devices and Radiological Health, discussing the direction that agency regulation is heading, "Schultz: de novo 510(k) path not used to 'maximum effect'."